Survival analysis and causes of mortality in patients with lupus nephritis

被引:246
作者
Yap, Desmond Y. H. [1 ]
Tang, Colin S. O. [1 ]
Ma, Maggie K. M. [1 ]
Lam, Man Fai [1 ]
Chan, Tak Mao [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Div Nephrol, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
end-stage renal disease; lupus nephritis; mortality; risk factor lupus; systemic erythematosus; LONG-TERM PROGNOSIS; MYCOPHENOLATE-MOFETIL; ACCELERATED ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; ERYTHEMATOSUS; DEATH; CYCLOPHOSPHAMIDE; COHORT; CLASSIFICATION; MORBIDITY;
D O I
10.1093/ndt/gfs073
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
This study aimed to define the causes and associated risks of death compared with the local general population in Chinese patients with lupus nephritis in the recent era. The records of all lupus nephritis patients followed in a single centre during 19682008 were reviewed. The causes of death were identified, the survival curves constructed and the standardized mortality ratios (SMRs) of potential risk factors were calculated with reference to the local general population. Two hundred and thirty systemic lupus erythematosus patients with history of renal involvement (predominantly Class III/IV lupus nephritis with or without membranous features) were included. The follow-up was 4076.6 person-years (mean 17.7 8.9 years). Twenty-four patients (10.4) died, and 85 of the deaths occurred after 10 years of follow-up. The 5-, 10-, and 20-year survival rates were 98.6, 98.2 and 90.5, respectively. The leading causes of death were infection (50.0), cardiovascular disease (20.8) and malignancy (12.5). The renal survival rates at 5, 10 and 20 years were 99.5, 98.0 and 89.7, respectively. The SMR in patients with renal involvement, end-stage renal disease (ESRD), malignancy or cardiovascular disease was 5.9, 26.1, 12.9 and 13.6, respectively. Lupus nephritis is associated with a 6-fold increase in mortality compared with the general population. Lupus patients who develop ESRD have a 26-fold excess in the risk of death, which is more than twice the risk associated with malignancy or cardiovascular disease in these patients.
引用
收藏
页码:3248 / 3254
页数:7
相关论文
共 48 条
[1]  
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259
[2]   Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].
Appel, Gerald B. ;
Contreras, Gabriel ;
Dooley, Mary Anne ;
Ginzler, Ellen M. ;
Isenberg, David ;
Jayne, David ;
Li, Lei-Shi ;
Mysler, Eduardo ;
Sanchez-Guerrero, Jorge ;
Solomons, Neil ;
Wofsy, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112
[3]   Premature coronary-artery atherosclerosis in systemic lupus erythematosus [J].
Asanuma, Y ;
Oeser, A ;
Shintani, AK ;
Turner, E ;
Olsen, N ;
Fazio, S ;
Linton, MF ;
Raggi, P ;
Stein, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2407-2415
[4]   THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS [J].
AUSTIN, HA ;
KLIPPEL, JH ;
BALOW, JE ;
LERICHE, NGH ;
STEINBERG, AD ;
PLOTZ, PH ;
DECKER, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) :614-619
[5]  
Bellomio V, 2000, LUPUS, V9, P377
[6]   The relationship between cancer and medication exposures in systemic lupus erythaematosus:: a case-cohort study [J].
Bernatsky, S. ;
Joseph, L. ;
Boivin, J-F ;
Gordon, C. ;
Urowitz, M. ;
Gladman, D. ;
Fortin, P. R. ;
Ginzler, E. ;
Bae, S-C ;
Barr, S. ;
Edworthy, S. ;
Isenberg, D. ;
Rahman, A. ;
Petri, M. ;
Alarcon, G. S. ;
Aranow, C. ;
Dooley, M-A ;
Rajan, R. ;
Senecal, J-L ;
Zummer, M. ;
Manzi, S. ;
Ramsey-Goldman, R. ;
Clarke, A. E. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (01) :74-79
[7]   Mortality in systemic lupus erythematosus [J].
Bernatsky, S. ;
Boivin, J. -F. ;
Joseph, L. ;
Manzi, S. ;
Ginzler, E. ;
Gladman, D. D. ;
Urowitz, M. ;
Fortin, P. R. ;
Petri, M. ;
Barr, S. ;
Gordon, C. ;
Bae, S. -C. ;
Isenberg, D. ;
Zoma, A. ;
Aranow, C. ;
Dooley, M. -A. ;
Nived, O. ;
Sturfelt, G. ;
Steinsson, K. ;
Alarcon, G. ;
Senecal, J. -L. ;
Zummer, M. ;
Hanly, J. ;
Ensworth, S. ;
Pope, J. ;
Edworthy, S. ;
Rahman, A. ;
Sibley, J. ;
El-Gabalawy, H. ;
McCarthy, T. ;
Pierre, Y. St. ;
Clarke, A. ;
Ramsey-Goldman, R. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2550-2557
[8]   An International Cohort Study of Cancer in Systemic Lupus Erythematosus [J].
Bernatsky, S ;
Boivin, JF ;
Joseph, L ;
Rajan, R ;
Zoma, A ;
Manzi, S ;
Ginzler, E ;
Urowitz, M ;
Gladman, D ;
Fortin, PR ;
Petri, M ;
Edworthy, S ;
Barr, S ;
Gordon, C ;
Bae, SC ;
Sibley, J ;
Isenberg, D ;
Rahman, A ;
Aranow, C ;
Dooley, MA ;
Steinsson, K ;
Nived, O ;
Sturfelt, G ;
Alarcón, G ;
Senécal, JL ;
Zummer, M ;
Hanly, J ;
Ensworth, S ;
Pope, J ;
El-Gabalawy, H ;
McCarthy, T ;
Pierre, YS ;
Ramsey-Goldman, R ;
Clarke, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1481-1490
[9]   The very long-term prognosis and complications of lupus nephritis and its treatment [J].
Bono, L ;
Cameron, JS ;
Hicks, JA .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1999, 92 (04) :211-218
[10]   US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV) [J].
Burgos, Paula I. ;
McGwin, Gerald, Jr. ;
Pons-Estel, Guillermo J. ;
Reveille, John D. ;
Alarcon, Graciela S. ;
Vila, Luis M. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (02) :393-U193